Preyer Linda, Vettorazzi Eik, Fiedler Walter, Rohde Holger, Stemler Jannik, Gönner Saskia, Bokemeyer Carsten, Khandanpour Cyrus, Wortmann Friederike, Kebenko Maxim
Hubertus Wald Tumorzentrum, Department of Oncology-Hematology, Bone Marrow Transplantation and Pneumology, University Cancer Center, Hamburg, Germany.
Department for Trauma Surgery, Orthopedics and Hand Surgery Städtisches Klinikum, Solingen, Germany.
Front Oncol. 2024 Oct 17;14:1429221. doi: 10.3389/fonc.2024.1429221. eCollection 2024.
Our monocentric and retrospective study aimed to investigate the clinical effectivity of HEPA filters in combination with the antifungal drug prophylaxis in patients with AML undergoing intensive chemotherapy and allogeneic stem cell transplantation (SCT).
METHODS/RESULTS: We included 177 patients between 2005 and 2015 representing a total of 372 in-hospital stays, 179 in the HEPA cohort (+HEPA) and 193 in the cohort without HEPA filters (-HEPA). No significant additional benefit of HEPA filtration on the risk reduction of IFI was observed. HEPA filtration did not significantly affect the risk of intensive care unit (ICU) admissions or early mortality rates. In patients who received allogeneic SCT in first complete remission with antifungal drug prophylaxis during prior induction treatment, a numerical but not significant improvement in long-term overall survival was noted in the +HEPA cohort compared to the -HEPA cohort (55% to 66%, p = 0.396). For better depicting of the clinical reality, we determined the so-called clinical suspected IFI (csIFI) -defined as cases with antifungal treatment after recommended prophylaxis without fulfilling current EORTC criteria. Especially in patients with a high risk for second IFI, significant risk reduction of csIFI and frequency of ICU admissions was observed when voriconazole was used as secondary antifungal prophylaxis. (csIFI, adjusted effect: OR 0.41, 95% CI (0.21 - 0.82), p = 0.01; csIFI, subgroup-specific effect: OR 0.35, 95% CI (0.15 - 0.78), p = 0.01; ICU, adjusted effect: OR 0.44, 95 CI (0.19 - 1.01), p = 0.05; respectively).
In summary, the study suggests the efficacy of secondary antifungal prophylaxis in preventing IFI in AML patients undergoing intensive treatment. The addition of HEPA filtration also demonstrated additional numerous benefits in reducing the frequency of IFI-associated complications.
我们的单中心回顾性研究旨在调查高效空气过滤器(HEPA)联合抗真菌药物预防措施对接受强化化疗和异基因干细胞移植(SCT)的急性髓系白血病(AML)患者的临床有效性。
方法/结果:我们纳入了2005年至2015年间的177例患者,共计372次住院,其中179例在HEPA队列(+HEPA),193例在无HEPA过滤器的队列(-HEPA)。未观察到HEPA过滤对降低侵袭性真菌感染(IFI)风险有显著的额外益处。HEPA过滤对重症监护病房(ICU)入住风险或早期死亡率无显著影响。在首次完全缓解期接受异基因SCT且在先前诱导治疗期间接受抗真菌药物预防的患者中,与-HEPA队列相比,+HEPA队列的长期总生存率有数值上的改善,但无统计学意义(55%对66%,p = 0.396)。为了更好地描述临床实际情况,我们确定了所谓的临床疑似IFI(csIFI),定义为在推荐预防后接受抗真菌治疗但未达到当前欧洲癌症研究与治疗组织(EORTC)标准的病例。特别是在第二次IFI高风险患者中,当伏立康唑用作二线抗真菌预防时,观察到csIFI和ICU入住频率显著降低。(csIFI,校正效应:比值比(OR)0.41,95%置信区间(CI)(0.21 - 0.82),p = 0.01;csIFI,亚组特异性效应:OR 0.35,95% CI(0.15 - 0.78),p = 0.01;ICU,校正效应:OR 0.44,95 CI(0.19 - 1.01),p = 0.05;分别)。
总之,该研究表明二线抗真菌预防在预防接受强化治疗的AML患者IFI方面的有效性。添加HEPA过滤在降低IFI相关并发症频率方面也显示出诸多额外益处。